Diranersen's Phase 2 results can establish that the drug does what it was designed to do biologically — it lowers tau protein in the brain and spinal fluid — but they cannot establish that it slows Alzheimer's disease. The CELIA trial missed its primary endpoint, which means the clinical benefit reported in the headlines came from secondary measures that a trial of this size cannot prove on their own. Diranersen (also called BIIB080, formerly IONIS-MAPTRx) is an investigational antisense oligonucleotide — a short strand of genetic material that binds to the messenger RNA for the tau gene and reduces how much tau protein the brain makes. According to the Ionis Pharmaceuticals investor release, it targets both tau inside and outside brain cells and is given by intrathecal injection — into the fluid around the spinal cord.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What CELIA actually tested, and what it found
- The secondary numbers, and why the dose pattern matters
- The tau evidence is stronger than the cognitive evidence
- Safety, and what intrathecal dosing means in practice
- What this means if you or a family member has early Alzheimer's
- How to read the next round of Alzheimer's headlines
- Frequently Asked Questions
What CELIA actually tested, and what it found
CELIA randomized 416 people who had never taken an anti-amyloid drug and who had either mild cognitive impairment due to Alzheimer's or mild Alzheimer's dementia. Participants received placebo or one of three regimens — 60 mg every 24 weeks, 115 mg every 24 weeks, or 115 mg every 12 weeks — over a 76-week placebo-controlled period. The primary endpoint was a dose-response analysis of change on the Clinical Dementia Rating–Sum of Boxes (CDR-SB), a scale that rates memory, judgment, home life, and personal care.
Biogen's topline release states plainly that the study did not meet it. A missed primary endpoint is the result of the trial. Everything reported afterward is a secondary analysis, and secondary analyses are generated in large numbers within a single study, which makes some of them look impressive by chance alone.
The secondary numbers, and why the dose pattern matters
At the Alzheimer's Association International Conference in London in July 2026, Biogen presented pre-specified secondary comparisons. The 60 mg every-24-weeks dose showed roughly 42% slowing on ADAS-Cog13 (a cognitive test), 50% on MMSE (a brief mental status exam), and 26% on CDR-SB versus placebo. Those percentages are large. The problem is the pattern behind them: the lowest dose outperformed the higher doses.
A drug that works through the mechanism claimed should generally do more when there is more of it, at least until side effects intervene. Biogen describes this as a non-linear exposure-response relationship. That is a legitimate possibility in biology, but it is also exactly what random variation looks like when one of several small subgroups happens to do well. Phase 2 cannot tell the two apart, which is the central limit of this dataset.
The tau evidence is stronger than the cognitive evidence
The biological results are on firmer ground. Biogen's AAIC release reports mean reductions of 50–65% in cerebrospinal fluid total tau, plus reduced brain tau tangle burden on tau PET imaging, across all doses studied. Biogen frames this as the first Phase 2 evidence that a drug can remove tau pathology in early Alzheimer's.
That consistency across doses is what a real drug effect usually looks like — and it is the opposite of the cognitive pattern, where only one dose stood out. But removing tau is a biomarker result, not a clinical one. Alzheimer's research has repeatedly produced drugs that moved a biomarker in the intended direction without changing how patients functioned. Tau tangles correlate closely with symptoms, which is why this target is attractive, but correlation in observational data does not guarantee that removing tangles restores or preserves function.
Safety, and what intrathecal dosing means in practice
Safety across doses was broadly consistent with the earlier Phase 1b study. However, serious adverse events were more frequent in the highest-dose cohort — which matters more than usual here, because the drug is delivered into the spinal fluid and would be taken indefinitely. Intrathecal administration is not a clinic-visit injection in the arm.
It requires a lumbar puncture performed by trained staff, carries its own risks including headache and infection, and would need to be repeated every 12 or 24 weeks for years. There is an unintended benefit in the dose findings: if the 60 mg every-24-weeks regimen really is the best-performing dose, the most effective option would also be the least frequent and the lowest exposure. That is a favorable combination — if Phase 3 confirms it.
What this means if you or a family member has early Alzheimer's
Nothing here changes a treatment plan today. Diranersen is not approved by the FDA or any other regulator and is available only through clinical trials, according to the Alzforum therapeutics entry. It received FDA Fast Track designation in 2025, which shortens review timelines but says nothing about whether the drug works.
Biogen has said it will advance diranersen into Phase 3 despite the missed primary endpoint. That confirmatory trial — not CELIA — is what could establish clinical efficacy, and Phase 3 programs in Alzheimer's typically run for years before reporting. Practical steps while that plays out:.
- Treat percentage figures from any Phase 2 trial as a hypothesis, not a result — ask whether the primary endpoint was met before anything else.
- Ask a neurologist about trial eligibility if you are at the mild cognitive impairment or mild dementia stage; CELIA enrolled people who had not taken an anti-amyloid drug, and future trials may have similar entry criteria.
- Search ClinicalTrials.gov for diranersen Phase 3 sites rather than waiting for a press release to name them.
- Be skeptical of any clinic offering tau-lowering therapy outside a registered trial — there is no approved product to offer.
How to read the next round of Alzheimer's headlines
The Alzheimer's Association's statement on CELIA makes the framing explicit: Phase 2 trials are designed only to give an early signal about whether a treatment may work and is safe enough to test in a larger group. It adds that more must be learned about the benefit and safety profile before conclusions can be drawn for people living with Alzheimer's.
Applied to future coverage, that yields three questions worth asking of any trial story. Did the study meet its primary endpoint? Are the reported benefits from the whole trial population or from one dose group? And is the outcome a biomarker or something the patient or family would notice? On those three questions, CELIA answers: no, one dose group, and a biomarker. A drug can still succeed from that position — several have — but the case rests on a trial that has not yet been run.
Frequently Asked Questions
Is diranersen the same kind of drug as lecanemab or donanemab?
No. Those target amyloid plaques; diranersen targets tau by reducing how much of the protein the brain produces. CELIA specifically enrolled people who had never taken an anti-amyloid drug.
Why would a company move to Phase 3 after missing the primary endpoint?
Because the tau reductions were consistent across every dose studied, giving a biological rationale to test a single chosen dose in a larger trial designed to answer the clinical question directly.
Does Fast Track designation mean approval is close?
No. Fast Track speeds regulatory interaction and review for drugs addressing serious conditions. It is granted before efficacy is established and does not predict whether the drug will be approved.
